NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $29.43 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$28.94 -0.49 (-1.65%) As of 09/25/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Adaptive Biotechnologies Stock (NASDAQ:ADPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADPT alerts:Sign Up Key Stats Today's Range$28.88▼$29.9650-Day Range$21.86▼$29.5752-Week Range$12.00▼$29.96Volume1.69 million shsAverage Volume2.14 million shsMarket Capitalization$4.70 billionP/E RatioN/ADividend YieldN/APrice Target$27.07Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies Corp. (NASDAQ: ADPT) is a biotechnology company focused on applying immune-system data to the diagnosis and treatment of disease. The company develops technologies that decode T-cell and B-cell receptors, helping researchers and clinicians analyze the adaptive immune response at the scale of individual immune cells. Its key products include clonoSEQ, a clinical diagnostic test that measures minimal residual disease in certain blood cancers, including multiple myeloma and acute lymphoblastic leukemia. Adaptive also offers immunoSEQ, a research platform that uses immune repertoire sequencing for applications in immunology, oncology, infectious disease and other areas of biomedical research. Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies serves pharmaceutical and biotechnology companies, academic researchers, healthcare providers and patients. The company has pursued partnerships and collaborations designed to apply its immune-repertoire technology to drug discovery, clinical development and precision medicine in the United States and international markets.AI Generated. May Contain Errors. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreADPT MarketRank™: Adaptive Biotechnologies scored higher than 32% of companies evaluated by MarketBeat, and ranked 755th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskAdaptive Biotechnologies has a consensus price target of $27.07, representing about 8.0% downside from its current price of $29.43.Amount of Analyst CoverageAdaptive Biotechnologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.40) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -71.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -71.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 20.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.96% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.89.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 15.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.51 News SentimentAdaptive Biotechnologies has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.Search Interest8 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,861,901.00 in company stock.Percentage Held by Insiders5.70% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADPT Stock News HeadlinesAdaptive Biotechnologies Spotlights MRD Testing In Myeloma Cure CriteriaSeptember 26 at 8:02 AM | rttnews.comAdaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline UpdateSeptember 25 at 8:00 PM | finance.yahoo.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?September 25 at 3:00 PM | finance.yahoo.comAdaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of CureSeptember 25 at 8:03 AM | globenewswire.comNCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)September 24, 2026 | finance.yahoo.comInsider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $3,238,292.36 in StockSeptember 19, 2026 | insidertrades.comSusan Bobulsky Sells 1,195 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) StockSeptember 18, 2026 | insidertrades.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $16.24 at the start of the year. Since then, ADPT shares have increased by 81.2% and is now trading at $29.43. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.12. Adaptive Biotechnologies's quarterly revenue was up 21.5% on a year-over-year basis. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $278 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' top institutional shareholders include BlackRock Inc. (9.49%), Wellington Management Group LLP (3.70%), Bank of America Corp DE (1.08%) and Freestone Grove Partners LP (0.55%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Tycho Peterson, Susan Bobulsky, Julie Rubinstein, Kyle Piskel, Sharon Benzeno, Francis Lo, Stacy L Taylor, Peter M Neupert, Michelle Renee Griffin and Robert Hershberg. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings7/29/2026Today9/27/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ADPT's financial health is in the Green zone, according to TradeSmith. ADPT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ADPT CIK1478320 Webwww.adaptivebiotech.com Phone(206) 659-0067Fax206-659-0667Employees624Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$27.07 High Price Target$34.00 Low Price Target$19.00 Potential Upside/Downside-8.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.50 million Net Margins-20.73% Pretax Margin-20.77% Return on Equity-36.81% Return on Assets-13.77% Debt Debt-to-Equity Ratio2.22 Current Ratio4.79 Quick Ratio4.68 Sales & Book Value Annual Sales$276.98 million Price / Sales16.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book20.02Miscellaneous Outstanding Shares159,600,000Free Float150,499,000Market Cap$4.70 billion OptionableOptionable Beta2.09 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ADPT) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts